Get the Stockscreener App
6.98
4.49%
0.30
After Hours:
6.84
-0.14
-2.01%
Climb Bio Inc stock is traded at $6.98, with a volume of 546.63K.
It is up +4.49% in the last 24 hours and down -1.55% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
See More
Previous Close:
$6.68
Open:
$6.79
24h Volume:
546.63K
Relative Volume:
0.78
Market Cap:
$333.42M
Revenue:
-
Net Income/Loss:
$-59.85M
P/E Ratio:
-7.8808
EPS:
-0.8857
Net Cash Flow:
$-54.54M
1W Performance:
-1.97%
1M Performance:
-1.55%
6M Performance:
+232.38%
1Y Performance:
+436.92%
1-Day Range:
$6.61
$7.00
1-Week Range:
$5.87
$7.22
52-Week Range:
$1.05
$8.04
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
6.98 | 319.09M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Mar-05-26 | Initiated | Wedbush | Outperform |
| Feb-13-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | William Blair | Outperform |
| Oct-13-25 | Initiated | H.C. Wainwright | Buy |
| Aug-15-25 | Initiated | Robert W. Baird | Outperform |
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
View All
Climb Bio Inc Stock (CLYM) Latest News
B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo
B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
If You Invested $1,000 in Climb Bio (CLYM) - Stock Titan
Aug Breakouts: Is Climb Bio Inc forming a double bottom2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com Australia
Truist initiates Climb Bio stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - MarketBeat
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Analysts’ Weekly Ratings Updates for Climb Bio (CLYM) - Defense World
Raymond James starts Climb Bio, Inc. (CLYM) at Strong Buy March 2026 - Meyka
Research Analysts Issue Forecasts for Climb Bio Q1 Earnings - Defense World
Climb Bio (NASDAQ:CLYM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for Climb Bio Issued By HC Wainwright - MarketBeat
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline - Investing.com UK
Raymond James initiates Climb Bio stock coverage with strong buy on renal pipeline By Investing.com - Investing.com South Africa
Climb Bio (NASDAQ:CLYM) Hits New 52-Week High After Analyst Upgrade - MarketBeat
Climb Bio (NASDAQ:CLYM) Price Target Raised to $15.00 - MarketBeat
Climb Bio price target raised to $11 from $9 at HC Wainwright - MSN
Climb Bio (NASDAQ:CLYM) Research Coverage Started at Wedbush - Defense World
Published on: 2026-03-08 04:23:03 - baoquankhu1.vn
HC Wainwright forecasts 2026 data readouts for Climb Bio’s (CLYM) Budoprutug across clinical tracks - MSN
Analysts Offer Insights on Healthcare Companies: Climb Bio (CLYM), ArriVent BioPharma, Inc. (AVBP) and Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
Fed Meeting: Is Climb Bio Inc a stock for growth or value investors2025 Biggest Moves & Consistent Income Trade Ideas - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Wedbush Raises Price Target for CLYM, Maintains 'Outperform' Rat - GuruFocus
Baird Maintains "Outperform" Rating, Raises Price Target for CLY - GuruFocus
Climb Bio (NASDAQ:CLYM) Price Target Raised to $12.00 - MarketBeat
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):